Insurance services company CNO Financial Group (NYSE: CNO) missed Wall Street’s revenue expectations in Q3 2026 as sales rose 4.5% year on year to $688.2 million. Its non-GAAP profit of $1.90 per share was 72.3% above analysts’ consensus estimates.

Is now the time to buy CNO? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

CNO Financial Group’s third quarter results were marked by a notable divergence between revenue and profitability. While the company’s sales growth lagged Wall Street’s expectations, management pointed to robust operating leverage and disciplined expense management as key contributors to the quarter’s non-GAAP profit strength. CEO Gary Bhojwani highlighted the continued expansion of CNO’s agent network and “solid sales momentum across both divisions,” particularly in asset accumulation products and Medicare Supplement policies. The company’s investment portfolio also delivered a significant lift to margins, benefiting from sustained high new money rates and favorable alternative investment income.

Looking forward, CNO’s updated full-year guidance relies on maintaining expense discipline, optimizing capital deployment, and capitalizing on shifting market trends in Medicare. CFO Paul McDonough emphasized that operational efficiency and “continued growth in our FHLB program” will play major roles in supporting the company’s targeted free cash flow range. Management expects the ongoing transition in the Medicare market—where consumers are increasingly favoring Medicare Supplement products over Medicare Advantage—to fuel further growth, with Bhojwani noting that “this dislocation plays to our strength” as a provider of both products and advisory services. Technology modernization and reinsurance strategies are also expected to shape CNO’s trajectory into 2027.

Key insights from management’s remarks

Management attributed the quarter’s margin expansion to favorable insurance product trends, a strong investment environment, and operational leverage from scale.

• Medicare shift accelerates: CNO experienced strong growth in Medicare Supplement sales, with management attributing this to industry-wide disruption in Medicare Advantage, as major carriers reduce benefits and exit markets. This trend is driving more consumers to seek advice and coverage through CNO’s agent network.
• Agent network expansion: The company reported its 15th consecutive quarter of producing agent count growth, which management credits for broadening distribution capabilities and deepening customer relationships, particularly in middle-income markets.
• Worksite momentum: Sales in the worksite division saw double-digit growth, driven by increased demand for voluntary employee benefits. Management identified small and mid-sized businesses as a growth engine, with new client acquisition up significantly over the quarter.
• Reinsurance optimization: CNO completed its third reinsurance transaction with its Bermuda affiliate, enabling improved capital efficiency and diversification across liabilities. Management views this as a foundation for future asset and capital optimization, particularly as the company settles into a “run rate cadence” in 2028 and beyond.
• Investment portfolio performance: Net investment income was a substantial contributor to earnings, supported by high-quality, short-duration structured credit assets and consistent new money yields above 6%. Management cautioned, however, that recent alternative investment outperformance may not be sustainable at current levels.

Drivers of future performance

CNO’s outlook is driven by operational efficiency, Medicare market trends, and disciplined capital allocation.

• Medicare market disruption: Management believes ongoing disruptions in Medicare Advantage will continue to shift demand toward Medicare Supplement products. As more consumers seek advice during plan transitions, CNO expects its agent-centric model to capture share and drive policy sales.
• Expense discipline and leverage: The company expects further improvement in its expense ratio through scale and operating leverage, with management citing opportunities for continued cost efficiencies even as investment in technology modernization remains a priority.
• Capital management and reinsurance: CNO’s capital strategy centers on optimizing its Bermuda reinsurance structure to support free cash flow and return on equity targets. Management indicated that future asset optimization within Bermuda, subject to regulatory approval, will be a key focus for 2027.

Catalysts in upcoming quarters

In the coming quarters, our analysts will monitor (1) the pace of Medicare Supplement policy growth as industry disruption continues, (2) execution of expense controls and technology modernization initiatives, and (3) progress on optimizing Bermuda reinsurance assets and capital. The sustainability of investment income and the ability to maintain agent productivity will also be important markers of CNO’s execution.

CNO Financial Group currently trades at $56.93, up from $55.17 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.